ES2903412T3 - Anticuerpos anti-IL-22R - Google Patents

Anticuerpos anti-IL-22R Download PDF

Info

Publication number
ES2903412T3
ES2903412T3 ES17746011T ES17746011T ES2903412T3 ES 2903412 T3 ES2903412 T3 ES 2903412T3 ES 17746011 T ES17746011 T ES 17746011T ES 17746011 T ES17746011 T ES 17746011T ES 2903412 T3 ES2903412 T3 ES 2903412T3
Authority
ES
Spain
Prior art keywords
antibody
seq
antibodies
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17746011T
Other languages
English (en)
Spanish (es)
Inventor
Christophe Frederic Jerome Blanchetot
Birgitte Ursø
Tine Skak-Nielsen
Malene Bertelsen
Der Woning Sebastian Van
Michael Saunders
Haard Johannes Joseph Wilhelmus De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Application granted granted Critical
Publication of ES2903412T3 publication Critical patent/ES2903412T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES17746011T 2016-07-15 2017-07-14 Anticuerpos anti-IL-22R Active ES2903412T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612337.4A GB201612337D0 (en) 2016-07-15 2016-07-15 Ant-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies

Publications (1)

Publication Number Publication Date
ES2903412T3 true ES2903412T3 (es) 2022-04-01

Family

ID=56890507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17746011T Active ES2903412T3 (es) 2016-07-15 2017-07-14 Anticuerpos anti-IL-22R

Country Status (28)

Country Link
US (4) US10696741B2 (cg-RX-API-DMAC10.html)
EP (2) EP3484921B1 (cg-RX-API-DMAC10.html)
JP (1) JP7163275B2 (cg-RX-API-DMAC10.html)
KR (2) KR102571012B1 (cg-RX-API-DMAC10.html)
CN (1) CN109641966B (cg-RX-API-DMAC10.html)
AU (1) AU2017296094B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019000788A2 (cg-RX-API-DMAC10.html)
CA (1) CA3024370A1 (cg-RX-API-DMAC10.html)
CY (1) CY1125041T1 (cg-RX-API-DMAC10.html)
DK (1) DK3484921T3 (cg-RX-API-DMAC10.html)
ES (1) ES2903412T3 (cg-RX-API-DMAC10.html)
GB (1) GB201612337D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20220197T1 (cg-RX-API-DMAC10.html)
HU (1) HUE057615T2 (cg-RX-API-DMAC10.html)
IL (1) IL264262B2 (cg-RX-API-DMAC10.html)
LT (1) LT3484921T (cg-RX-API-DMAC10.html)
MX (1) MX2019000539A (cg-RX-API-DMAC10.html)
MY (1) MY197821A (cg-RX-API-DMAC10.html)
PL (1) PL3484921T3 (cg-RX-API-DMAC10.html)
PT (1) PT3484921T (cg-RX-API-DMAC10.html)
RS (1) RS62884B1 (cg-RX-API-DMAC10.html)
RU (1) RU2758721C2 (cg-RX-API-DMAC10.html)
SA (1) SA519400856B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201900128XA (cg-RX-API-DMAC10.html)
SI (1) SI3484921T1 (cg-RX-API-DMAC10.html)
UA (1) UA125585C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018011420A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807816B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
MX2020013243A (es) 2018-06-05 2021-05-12 Bioatla Inc Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
US20250339371A1 (en) 2022-06-03 2025-11-06 Leo Pharma A/S Liquid formulation of il-22r antibody
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
EA015706B1 (ru) * 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
JP2009518314A (ja) * 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
MX2012005791A (es) * 2009-11-19 2012-07-03 Merck Serono Sa Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
AU2013310924B2 (en) 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014133728A2 (en) * 2013-03-01 2014-09-04 Albert Einstein College Of Medicine Of Yeshiva University Hhla2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
IL264262B2 (en) 2024-11-01
WO2018011420A1 (en) 2018-01-18
NZ748737A (en) 2025-06-27
US10696741B2 (en) 2020-06-30
PT3484921T (pt) 2022-01-26
US11261246B2 (en) 2022-03-01
CY1125041T1 (el) 2023-03-24
SG11201900128XA (en) 2019-02-27
KR20190026766A (ko) 2019-03-13
SI3484921T1 (sl) 2022-02-28
EP3484921B1 (en) 2021-11-17
IL264262A (en) 2019-02-28
US20190127459A1 (en) 2019-05-02
HRP20220197T1 (hr) 2022-04-29
ZA201807816B (en) 2026-03-25
PL3484921T3 (pl) 2022-03-28
UA125585C2 (uk) 2022-04-27
JP2019528046A (ja) 2019-10-10
US20200157207A1 (en) 2020-05-21
EP4023674A3 (en) 2022-10-05
BR112019000788A2 (pt) 2019-07-02
CN109641966B (zh) 2022-08-23
EP3484921A1 (en) 2019-05-22
DK3484921T3 (da) 2022-02-07
RU2019103991A (ru) 2020-08-17
GB201612337D0 (en) 2016-08-31
EP4023674A2 (en) 2022-07-06
LT3484921T (lt) 2022-01-10
MY197821A (en) 2023-07-18
SA519400856B1 (ar) 2022-10-25
US11447544B2 (en) 2022-09-20
RU2019103991A3 (cg-RX-API-DMAC10.html) 2021-04-29
US20200216528A1 (en) 2020-07-09
MX2019000539A (es) 2019-10-04
KR102571012B1 (ko) 2023-08-24
JP7163275B2 (ja) 2022-10-31
HUE057615T2 (hu) 2022-05-28
CA3024370A1 (en) 2018-01-18
KR20230128137A (ko) 2023-09-01
IL264262B1 (en) 2024-07-01
AU2017296094B2 (en) 2024-02-01
RS62884B1 (sr) 2022-03-31
AU2017296094A1 (en) 2018-12-13
CN109641966A (zh) 2019-04-16
US20230088269A1 (en) 2023-03-23
RU2758721C2 (ru) 2021-11-01

Similar Documents

Publication Publication Date Title
ES2594493T3 (es) Anticuerpos anti-c-Met
US11447544B2 (en) Anti-IL-22R antibodies
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
KR102598319B1 (ko) 항-il-25 항체 및 그의 용도
CN119365488A (zh) 抗bdca2抗体及其用途
JP7256266B2 (ja) ヒトＩＬ－１βに結合する抗体、その調製方法及び用途
US20240343799A1 (en) ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF
WO2024094017A1 (zh) 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
CN111787980B (zh) 非酒精性脂肪性肝炎的抗huTNFR1疗法
HK40075871A (en) Anti-il-22r antibodies
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
WO2025223473A1 (zh) 抗gdf-15抗体及其应用
AU2024247517A1 (en) Anti-il-25 antibodies and methods of use thereof
HK40006087A (en) Anti-il-22r antibodies
HK40006087B (en) Anti-il-22r antibodies